# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(1.07...
Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transfo...
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and contin...
UBS analyst Eliana Merle maintains Kodiak Sciences (NASDAQ:KOD) with a Neutral and raises the price target from $3 to $5.
Barclays analyst Gena Wang maintains Kodiak Sciences (NASDAQ:KOD) with a Underweight and raises the price target from $2 to $3.
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...